Skip to main content
 
 
 
MENU
VISIT JANSSEN GLOBAL

EMEA
change location▼

Search
Search
COVID-19 UPDATES >

VISIT JANSSEN GLOBAL

COVID-19 UPDATES >
Janssen EMEA › Media Center

Media Center

The Media Center is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Dec 03, 2021

Latest Phase 3 Data for First-in-Class TREMFYA®▼ (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumour Necrosis Factor Inhibition (TNFi-IR)

Nov 30, 2021

Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

Nov 30, 2021

Janssen Seeks Approval of IMBRUVICA®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)

Nov 29, 2021

Johnson & Johnson to Evaluate its COVID-19 Vaccine Against New Omicron COVID-19 Variant

Nov 23, 2021

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

Nov 22, 2021

Johnson & Johnson Announces Submission of Application to the European Medicines Agency (EMA) for use of its COVID-19 Vaccine as a Booster Dose 

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

The Role Of The Immune System In Crohn’s Disease

Stelara MOA infographic

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL